Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on April 1, 2026, to disclose a material event under Regulation FD. The company is a Delaware corporation headquartered in Doylestown, PA, and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing reports the closing of a private placement with gross proceeds of approximately $30 million. The document does not provide specific values for revenue, profit, operating cash flow, margins, existing debt levels, or liquidity ratios beyond the new capital raised.
Material Changes
The primary material change is the successful closing of the previously announced private placement, resulting in an immediate increase in cash assets of approximately $30 million. No other financial changes or comparative period data are detailed in this specific filing.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the capital raise. The filing explicitly states that the press release and related information are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings unless expressly stated. No specific guidance, risk factors, or contingencies are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and transaction expenses.
- Confirm the number of shares issued and the price per share in the private placement.
- Review the attached Exhibit 99.1 (Press Release) for details on the use of proceeds.
- Check for any registration rights agreements or warrants issued alongside the equity.
- Assess the impact of the new capital on the company's cash runway and operational timeline.